GLPwatch
Papers (10372)
Page 25 of 173, ranked by citation count.
- Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.
- Exendin-4 analogs in insulinoma theranostics.
- Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury.
- Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
- Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.
- Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment.
- Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
- Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.
- Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
- Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents.
- Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice.
- Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
- Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
- GLP-1 and Its Analogs: Does Sex Matter?
- GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA.
- Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells.
- Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
- Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.
- Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
- The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis.
- Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.
- Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
- Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
- Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats.
- The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome.
- The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
- Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC).
- GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling.
- Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.
- Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
- Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.
- Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.
- Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
- Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels.
- Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
- Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.
- Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.
- Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
- A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
- Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.
- Clinical Pharmacokinetics of Semaglutide: A Systematic Review.
- Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
- New therapies for obesity.
- Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes.
- Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy.
- Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
- Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide.
- Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.
- A Long-Acting PYY<sub>3-36</sub> Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.
- A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
- Phasic dopamine responses to a food-predictive cue are suppressed by the glucagon-like peptide-1 receptor agonist Exendin-4.
- Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells.
- Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
- GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.